Biogen Inc. $BIIB Position Boosted by Farmers Trust Co.

Farmers Trust Co. boosted its position in Biogen Inc. (NASDAQ:BIIB) by 27.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 33,185 shares of the biotechnology company’s stock after buying an additional 7,214 shares during the period. Farmers Trust Co.’s holdings in Biogen were worth $5,840,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC bought a new position in Biogen during the 2nd quarter worth approximately $25,000. Rothschild Investment LLC increased its holdings in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the last quarter. Accredited Wealth Management LLC increased its holdings in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares during the last quarter. WFA of San Diego LLC acquired a new stake in shares of Biogen during the 2nd quarter valued at approximately $32,000. Finally, True Wealth Design LLC lifted its stake in Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $183.49 on Friday. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The business’s fifty day moving average price is $184.18 and its two-hundred day moving average price is $168.12. The firm has a market capitalization of $26.93 billion, a PE ratio of 20.83, a P/E/G ratio of 1.45 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Late‑breaking Phase 2 AMETHYST Part A data for litifilimab in cutaneous lupus (CLE) will be presented at the AAD meeting; the program already has FDA Breakthrough Therapy designation, which could materially increase the drug’s commercial value if further data confirm benefit. Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data
• Positive Sentiment: Biogen launched a Phase 3 fumarate study targeting pediatric multiple sclerosis, expanding potential addressable market and signaling management’s push for growth outside its core older-adult neurology franchises. Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study
• Positive Sentiment: BIIB080 Phase 1 imaging study completed — an early but necessary step in the Alzheimer’s program that reduces some development uncertainty and keeps the pipeline moving. Biogen’s BIIB080 Imaging Study Completes
• Positive Sentiment: An HSBC write‑up forecasting strong price appreciation for BIIB may bolster sentiment and buying interest from institutional investors. HSBC Forecasts Strong Price Appreciation for Biogen
• Neutral Sentiment: Biogen presented at the Stifel 2026 Virtual CNS Forum (investor transcript available) — useful for detail but unlikely to move the stock unless new guidance or surprises emerged. Biogen Presents at Stifel 2026 Virtual CNS Forum Transcript
• Neutral Sentiment: Short‑interest notices report a “significant increase” in March but show 0 shares / NaN change and a days‑to‑cover of 0.0 — the data look inconsistent, so treat any short‑pressure signal as uncertain until corrected.
• Negative Sentiment: The U.S. District Court for the District of Massachusetts certified a securities class action on behalf of Biogen purchasers, which introduces legal risk, potential costs and headline volatility. Securities Litigation Certified as Class Action

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Piper Sandler lifted their price objective on shares of Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Barclays assumed coverage on shares of Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price target on the stock. HC Wainwright lifted their price target on shares of Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a report on Monday, February 9th. TD Cowen boosted their price objective on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Royal Bank Of Canada increased their price objective on shares of Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $205.31.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.